Anti-BCMA antibodies
Inventors
TANG, Leyan • SCHULKINS, Allison • THAN, Kimberly • Chen, Chun-Nan • MIAO, Jingyun • Zhang, Xiaohui • Shi, Xiaojuan • Zhang, Lin
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12116415-B2
Publication Date
2024-10-15
Expiration Date
Abstract
Provided are antibodies that recognize the B-Cell Maturation Antigen (BCMA) and methods of use thereof.
Core Innovation
The invention relates to BCMA (TNFRSF17/CD269)-binding antibodies. The antibody is defined as binding human BCMA and is characterized by specified amino acid sequence sets, including SEQ ID NO:1 and alternative heavy-chain and light-chain CDR regions and variable-region sequence pairings that satisfy the BCMA-binding requirement.
The invention provides antibodies intended to bind BCMA on human BCMA and to target BCMA-expressing malignant or neoplastic B-cells. The document positions these antibodies within characterization of binding and functional activity against BCMA-associated targets.
The disclosed antibodies are supported by characterization data including binding assessment to BCMA, cell-surface binding, and ADCC potency against BCMA+ target cell lines, together with comparative benchmark elements. The overall concept is a BCMA-binding antibody product defined by sequence identifiers and CDR or variable-region compositions, optionally used in pharmaceutical contexts and detection or monitoring contexts described in the document.
Claims Coverage
The document includes three independent claims. Across these independent claims, the inventive focus is on defining an antibody that binds human BCMA by specified sequence identifiers and defined heavy/light chain components using multiple alternative CDR or V_H/V_L pairings.
Human BCMA binding defined by specified CDR amino acid sequences
An antibody that binds human BCMA comprising SEQ ID NO:1, where the antibody comprises selected CDRs with alternative HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 sequence sets.
Human BCMA binding defined by specified V_H and V_L sequence pairings
An antibody that binds human BCMA comprising SEQ ID NO:1, where the antibody comprises one selected pairing of V_H and V_L amino acid sequences from multiple alternatives.
Human BCMA binding defined by specified heavy-chain and light-chain sequence pairings
An antibody that binds human BCMA comprising SEQ ID NO:1, where the antibody comprises one selected pairing of heavy-chain and light-chain amino acid sequences from multiple alternatives.
Overall, the independent claims define BCMA-binding antibodies targeted to human BCMA using sequence identifiers and specified heavy/light chain components, with multiple alternative CDR configurations or multiple alternative V_H/V_L or heavy/light sequence pairings.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Therapeutic treatment of a subject with a BCMA-related cancer by administering the antibody or an antigen-binding fragment.
Targeting a BCMA-expressing cancer cell by administering the antibody or an antigen-binding fragment conjugated to a chemotherapeutic or radiotherapeutic.
Detecting BCMA in vitro by incubating the antibody with a sample comprising BCMA or an antigen thereof and detecting BCMA bound to the antibody.
Interested in licensing this patent?